It didn’t take long for Terry Ross, former president and CEO of PACS firm Cemax-Icon, to find a new job. Ross, who left the Fremont, CA-based firm following the close of its acquisition by Eastman Kodak in December (SCAN 12/16/98), has been
It didnt take long for Terry Ross, former president and CEO of PACS firm Cemax-Icon, to find a new job. Ross, who left the Fremont, CA-based firm following the close of its acquisition by Eastman Kodak in December (SCAN 12/16/98), has been named president of ultrafast CT developer Imatron of South San Francisco, CA. He has served as an Imatron board member for 12 years.
Ross is the second Cemax-Icon executive to leave the company in recent months. Former vice president of sales and marketing Oran Muduroglu left the company in 1998 to head up Stentor, a San Francisco startup formed to commercialize dynamic transfer syntax (DTS), a protocol for low-cost enterprise-wide image distribution developed by a University of Pittsburgh Medical Center PACS research team. A DTS demonstration drew much attention in the infoRAD exhibit area at last years RSNA meeting.
What a New Meta-Analysis Reveals About PET/CT Radiotracers for csPCa
February 6th 2025The PET/CT agent 18F-PSMA-1007 offered the highest surface under the cumulative ranking curve (SUCRA) out of nine radiotracers at the patient and lesion level for detecting clinically significant prostate cancer (csPCa), according to a meta-analysis.
New CT Angiography Study Shows Impact of COVID-19 on Coronary Inflammation and Plaque
February 5th 2025Prior COVID-19 infection was associated with a 28 percent higher progression of total percent atheroma volume (PAV) annually and over a 5 percent higher incidence of high-risk plaque in patients with coronary artery lesions, according to CCTA findings from a new study.